Encephalitis
MONDO:0019956An acute inflammatory process affecting the brain parenchyma. Causes include viral infections and less frequently bacterial infections, toxins, and immune-mediated processes.
Also known as: brain inflammation
97 clinical trials for this condition and its sub-types, 26 tagged with Encephalitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Encephalitis
-
Infectious encephalitis 3 trials · 50 incl. sub-types
10 sub-types
- Progressive multifocal leukoencephalopathy 19 trials
- Viral encephalitis 3 trials · 17 incl. sub-types Sub-types →
- Postinfectious encephalitis 0 trials · 13 incl. sub-types Sub-types →
- Hendra virus infection 0 trials
- Kluver-Bucy syndrome 0 trials
- Mycoplasma encephalitis 0 trials
- Acute necrotizing encephalopathy of childhood 0 trials
- Granulomatous amebic encephalitis 0 trials
- Primary amebic meningoencephalitis 0 trials
- Syphilitic encephalitis 0 trials
-
Autoimmune encephalitis 32 trials · 33 incl. sub-types
2 sub-types
-
Anti-NMDA receptor encephalitis 9 trials
-
Meningoencephalitis 6 trials
-
Limbic encephalitis 1 trial · 2 incl. sub-types
6 sub-types
- Autoimmune limbic encephalitis 1 trial
- Limbic encephalitis with DPP6 antibodies 0 trials
- Limbic encephalitis with caspr2 antibodies 0 trials
- Non-herpetic acute limbic encephalitis 0 trials
- Paraneoplastic limbic encephalitis 0 trials Sub-types →
- Posttransplant acute limbic encephalitis 0 trials
-
Post-vaccinal encephalitis 0 trials
Most studied deeper sub-types
-
Could an Immune-Modulating drug slow early Alzheimer's?
Disease control CompletedThis phase 2 trial investigates whether lenalidomide, a drug that calms inflammation, can slow cognitive decline in people with mild cognitive impairment due to Alzheimer's disease. Participants take lenalidomide or a placebo for up to 12 months, followed by a 6-month washout per…
Phase 2 • Sponsor: St. Joseph's Hospital and Medical Center, Phoenix • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New antibody drug aims to block brain attacks in autoimmune encephalitis
Disease control CompletedThis early-stage trial tested a new drug called ART5803 in 64 healthy adults to see if it is safe. ART5803 is a lab-made antibody designed to block harmful immune proteins that attack the brain in autoimmune encephalitis. The study gave single or multiple doses and compared them …
Phase 1 • Sponsor: Arialys Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
One-Hour brain infection test could save lives
Diagnosis CompletedThis study tested a new rapid diagnostic panel called QIAstat-Dx that can detect 15 different bacteria, viruses, and fungi causing meningitis and encephalitis in just one hour. Researchers compared its accuracy against standard lab tests using 170 stored spinal fluid samples. If …
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Can a web program rebuild memory after brain injury?
Symptom relief CompletedResearchers in Finland are testing a web-based neuropsychological rehabilitation program for adults who have recently had an acquired brain injury from causes such as stroke, encephalitis, or trauma. The program, called the iRENE Digital Pathway, uses online sessions and question…
Sponsor: Helsinki University Central Hospital • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Could music be medicine for the injured brain?
Symptom relief CompletedThis trial tests whether adding music therapy to standard rehabilitation helps people recover better after serious neurological injuries like stroke, brain injury, or spinal cord damage. About 75 participants aged 16-80 will be randomly assigned to receive either music therapy or…
Sponsor: University College, London • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Healthy volunteers help test new drug for brain inflammation
Knowledge-focused CompletedThis early-stage study tested a single dose of a new drug called ART5803 in 7 healthy adults to see if it is safe and how it interacts with another medicine (IVIG). The goal was to gather information for future research on autoimmune encephalitis, a condition where the immune sys…
Phase 1 • Sponsor: Arialys Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC